Clinical Trials
7 trialsNCT05681039 2026-06-02
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05286801 2026-05-13
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT05805501 2026-05-12
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT05645692 2026-04-29
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT05009069 2026-04-21
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT04543617 2026-04-17
SKYSCRAPER-07
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT06760481 2026-04-15
Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)
M.D. Anderson Cancer Center
Phase 1 Active not recruiting